Innovations in Progress

Changing the face of insulin pump therapy

The information below discusses products not approved by the FDA. This information is intended for investors researching the company, and is updated in conjunction with public announcements about our product pipeline. All dates and information below are as of October 16, 2019. Tandem undertakes no obligation to update or review any forward-looking information below based on new information, future events or other factors.



Automated Insulin Delivery

The t:slim X2 Insulin Pump with Control-IQ
Advanced Hybrid Closed-loop Technology

Currently under review by the FDA.

The t:slim X2 insulin pump with Control-IQ technology utilizes Dexcom G6 CGM sensor values to predict glucose levels 30 minutes ahead and adjust insulin delivery to help prevent highs and lows, while still allowing the user to manually bolus for meals. The system also delivers automatic correction boluses, which is a feature not commercially available today on automated insulin delivery devices.

Timelines as of 10/16/2019:
 - Pivotal clinical study through iDCL. Trial completed April 2019
 - Data published by New England Journal of Medicine in October 2019
 - Launch goal: Q4 2019

t:slim X2 Insulin Pump with Basal-IQ Technology